Assessment of immunogenicity and efficacy of a Zika vaccine using modified vaccinia Ankara virus as carriers

Assessment of immunogenicity and efficacy of a Zika vaccine using modified vaccinia Ankara virus as carriers

Zika virus (ZIKV) is an emerging mosquito-borne flavivirus that has spread to more than 70 countries worldwide since 2015. Despite active research, there are currently no licensed vaccines or therapeutics. We have previously reported the development of various adenoviral vectored vaccine candidates...

Disgrifiad llawn

Manylion Llyfryddiaeth
Prif Awduron:	López-Camacho, C, Kim, Y, Abbink, P, Larocca, R, Huiskonen, J, Barouch, D, Reyes-Sandoval, A
Fformat:	Journal article
Iaith:	English
Cyhoeddwyd:	MDPI 2019

Eitemau Tebyg

Assessment of Immunogenicity and Efficacy of a Zika Vaccine Using Modified Vaccinia Ankara Virus as Carriers
gan: César López-Camacho, et al.
Cyhoeddwyd: (2019-11-01)

Safety and immunogenicity of DNA/modified vaccinia virus ankara malaria vaccination in African adults.
gan: Moorthy, V, et al.
Cyhoeddwyd: (2003)

New approaches for improving the immunogenicity of modified vaccinia virus Ankara as a recombinant vaccine vector
gan: Alharbi, N
Cyhoeddwyd: (2014)

Clinical development of Modified Vaccinia virus Ankara vaccines.
gan: Gilbert, S
Cyhoeddwyd: (2013)

Clinical development of Modified Vaccinia virus Ankara vaccines
gan: Gilbert, S
Cyhoeddwyd: (2013)

Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans.
gan: McConkey, S, et al.
Cyhoeddwyd: (2003)

Safety and immunogenicity of novel recombinant BCG and modified vaccinia virus Ankara vaccines in neonate rhesus macaques.
gan: Rosario, M, et al.
Cyhoeddwyd: (2010)

Enhanced immunogenicity for CD8+ T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara.
gan: Schneider, J, et al.
Cyhoeddwyd: (1998)

Safety and immunogenicity of IMVAMUNE®, a third-generation vaccine based on the modified vaccinia Ankara (MVA) strain
gan: L. F. Stovba, et al.
Cyhoeddwyd: (2023-04-01)

Development of Modified Vaccinia Virus Ankara-Based Vaccines: Advantages and Applications
gan: Olga Vladimirovna Orlova, et al.
Cyhoeddwyd: (2022-09-01)

Low Immune Cross-Reactivity between West Nile Virus and a Zika Virus Vaccine Based on Modified Vaccinia Virus Ankara
gan: Nereida Jiménez de Oya, et al.
Cyhoeddwyd: (2022-03-01)

Immunogenicity and efficacy of Zika virus envelope domain III in DNA, protein, and ChAdOx1 adenoviral-vectored vaccines
gan: López-Camacho, C, et al.
Cyhoeddwyd: (2020)

Deletion of fifteen open reading frames from modified vaccinia virus Ankara fails to improve immunogenicity
gan: Alharbi, N, et al.
Cyhoeddwyd: (2015)

Deletion of Fifteen Open Reading Frames from Modified Vaccinia Virus Ankara Fails to Improve Immunogenicity.
gan: Naif Khalaf Alharbi, et al.
Cyhoeddwyd: (2015-01-01)

Immunogenicity and Safety of Modified Vaccinia Ankara (MVA) Vaccine—A Systematic Review and Meta-Analysis of Randomized Controlled Trials
gan: Lior Nave, et al.
Cyhoeddwyd: (2023-08-01)

Modified Vaccinia virus Ankara-based vaccines in the era of personalized immunotherapy of cancer
gan: Kaïdre Bendjama, et al.
Cyhoeddwyd: (2017-09-01)

Phase 2a safety and immunogenicity testing of DNA and recombinant modified vaccinia ankara virus vaccines expressing virus-like particles
gan: Goepfert P, et al.
Cyhoeddwyd: (2012-09-01)

Safety and immunogenicity of novel adenovirus type 26- and modified vaccinia Ankara-vectored Ebola vaccines: a randomized clinical trial
gan: Milligan, I, et al.
Cyhoeddwyd: (2016)

Immunogenicity and reactogenicity of novel adenovirus type 26 and modified vaccinia Ankara-vectored Ebola vaccines: A randomized clinical trial
gan: Milligan, I, et al.
Cyhoeddwyd: (2016)

Enhanced immunogenicity of CD4(+) t-cell responses and protective efficacy of a DNA-modified vaccinia virus Ankara prime-boost vaccination regimen for murine tuberculosis.
gan: Mcshane, H, et al.
Cyhoeddwyd: (2001)

Dendritic cells infected by recombinant modified vaccinia virus Ankara retain immunogenicity in vivo despite in vitro dysfunction.
gan: Behboudi, S, et al.
Cyhoeddwyd: (2004)

Immunogenicity and Efficacy of Zika Virus Envelope Domain III in DNA, Protein, and ChAdOx1 Adenoviral-Vectored Vaccines
gan: César López-Camacho, et al.
Cyhoeddwyd: (2020-06-01)

Reactogenicity and Immunogenicity Against MPXV of the Intradermal Administration of Modified Vaccinia Ankara Compared to the Standard Subcutaneous Route
gan: Valentina Mazzotta, et al.
Cyhoeddwyd: (2024-12-01)

Enhanced immunogenicity and protective efficacy against Mycobacterium tuberculosis of bacille Calmette-Guerin vaccine using mucosal administration and boosting with a recombinant modified vaccinia virus Ankara.
gan: Goonetilleke, N, et al.
Cyhoeddwyd: (2003)

The third generation modified vaccinia Ankara vaccine is effective in preventing the transmission of mpox
gan: Mingwang Shen, et al.
Cyhoeddwyd: (2024-10-01)

Ty virus-like particles, DNA vaccines and Modified Vaccinia Virus Ankara; comparisons and combinations.
gan: Gilbert, S, et al.
Cyhoeddwyd: (1999)

Modified Vaccinia Virus Ankara as a Viral Vector for Vaccine Candidates against Chikungunya Virus
gan: Juan García-Arriaza, et al.
Cyhoeddwyd: (2021-08-01)

Phase I safety and immunogenicity evaluation of MVA-CMDR, a multigenic, recombinant modified vaccinia Ankara-HIV-1 vaccine candidate.
gan: Jeffrey R Currier, et al.
Cyhoeddwyd: (2010-11-01)

Phase 1 safety and immunogenicity evaluation of ADMVA, a multigenic, modified vaccinia Ankara-HIV-1 B'/C candidate vaccine.
gan: Sandhya Vasan, et al.
Cyhoeddwyd: (2010-01-01)

Immunogenicities of intravenous and intramuscular administrations of modified vaccinia virus Ankara-based multi-CTL epitope vaccine for human immunodeficiency virus type 1 in mice.
gan: Hanke, T, et al.
Cyhoeddwyd: (1998)

Vaccination with a modified vaccinia virus Ankara (MVA)-vectored HIV-1 immunogen induces modest vector-specific T cell responses in human subjects.
gan: Howles, S, et al.
Cyhoeddwyd: (2010)

Improved Host Range Selection for Recombinant Modified Vaccinia Virus Ankara
gan: Caroline Staib, et al.
Cyhoeddwyd: (2003-04-01)

Elements in the Development of a Production Process for Modified Vaccinia Virus Ankara
gan: Volker Sandig, et al.
Cyhoeddwyd: (2013-11-01)

Next-generation mpox vaccines: efficacy of mRNA-1769 compared to modified vaccinia virus Ankara in non-human primates
gan: Leonie Mayer, et al.
Cyhoeddwyd: (2024-11-01)

Synthetic modified vaccinia Ankara vaccines confer cross-reactive and protective immunity against mpox virus
gan: Flavia Chiuppesi, et al.
Cyhoeddwyd: (2024-02-01)

The Efficacy of Disinfection on Modified Vaccinia Ankara and African Swine Fever Virus in Various Forest Soil Types
gan: Franziska Tanneberger, et al.
Cyhoeddwyd: (2021-10-01)

Ebola virus – prospects for a novel virus-like-particle-expressing modified vaccinia Ankara-based vaccine
gan: Harriet L. Robinson, et al.
Cyhoeddwyd: (2018-09-01)

Expanding the repertoire of Modified Vaccinia Ankara-based vaccine vectors via genetic complementation strategies.
gan: David A Garber, et al.
Cyhoeddwyd: (2009-01-01)

Correction: Next-generation mpox vaccines: efficacy of mRNA-1769 compared to modified vaccinia virus Ankara in non-human primates
gan: Leonie Mayer, et al.
Cyhoeddwyd: (2024-12-01)

Transient Host Range Selection for Genetic Engineering of Modified Vaccinia Virus Ankara
gan: C. Staib, et al.
Cyhoeddwyd: (2000-06-01)